FDA approved Vaxelis, a new combination DTaP-IPV-Hib-HepB vaccine for use in children 6 wks-4 yrs of age

, , , , ,

On Dec. 26, 2018, Sanofi announced the U.S. Food and Drug Administration (FDA) had approved VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age (prior to the 5th birthday).

VAXELIS is the result of the US-based joint-partnership established in 1991 between Merck and Sanofi Pasteur. VAXELIS includes antigens for diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis from Sanofi and antigens for H. influenzae type b and hepatitis B from Merck.

Tags:


Source: Sanofi Pasteur
Credit: